Pursuant to Regulation 26(7) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, Sanofi Consumer Healthcare India has informed that recommendations given by the Committee of Independent Directors at its meeting held on 10th April 2025 to the public shareholders on the open offer made by Opal Bidco SAS (‘Acquirer’) together with Clayton, Dubilier & Rice Fund XII, L.P., (a person acting in concert with the Acquirer), has been published today 11th April 2025 in the newspapers: The Financial Express (English) in All editions, Jansatta (Hindi) in All editions, Navshakti (Marathi) in Mumbai editions. A copy of the publication is enclosed and the same is also available on the website of the Company at Newspaper Advertisement.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: